GF Fund Management CO. LTD. Takes Position in argenx SE (NASDAQ:ARGX)

GF Fund Management CO. LTD. bought a new stake in argenx SE (NASDAQ:ARGX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 677 shares of the company's stock, valued at approximately $416,000.

A number of other institutional investors also recently modified their holdings of the business. Point72 Europe London LLP acquired a new position in argenx during the fourth quarter worth about $5,839,000. Stephens Inc. AR bought a new position in argenx in the 4th quarter valued at approximately $310,000. Jones Financial Companies Lllp raised its position in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after purchasing an additional 61 shares during the last quarter. Atomi Financial Group Inc. bought a new position in argenx during the 4th quarter worth approximately $339,000. Finally, Ameriprise Financial Inc. raised its position in shares of argenx by 10.0% in the 4th quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock worth $4,313,000 after acquiring an additional 639 shares in the last quarter. Institutional investors own 60.32% of the company's stock.

argenx Price Performance

ARGX stock traded down $3.53 during mid-day trading on Wednesday, hitting $576.24. 230,594 shares of the stock were exchanged, compared to its average volume of 325,666. The business has a fifty day moving average price of $588.46 and a 200 day moving average price of $612.85. argenx SE has a 12 month low of $359.37 and a 12 month high of $678.21. The stock has a market capitalization of $35.19 billion, a price-to-earnings ratio of -654.82 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.26. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $748.34 million. As a group, equities analysts forecast that argenx SE will post 3.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ARGX has been the subject of several recent research reports. Citigroup reissued a "buy" rating on shares of argenx in a research report on Wednesday, May 21st. Sanford C. Bernstein raised shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. William Blair restated an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Oppenheimer upped their price objective on argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Finally, Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, twenty have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, argenx presently has a consensus rating of "Buy" and a consensus target price of $698.11.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.